Objective: To verify the effects on the lipid pro®le of a product of fermented milk (Gaio 1 ) in patients with mild to moderate primary hypercholesterolemia. Design: The study was prospective, randomized, double-blinded and placebo controlled, with a crossover design. Subjects: Thirty-two patients (21 women and 11 men) with ages ranging between 36 and 65 years old were included in the study. All of them were on a controlled diet for at least 8 weeks. Intervention: Patients began, after clinical and laboratory analysis, in a randomized and double-blind manner to take 200 g daily of Gaio 1 or its placebo. After 8 weeks blood was collected again for lipid pro®le evaluation and the crossover was made. After an additional 8 weeks blood was collected for another lipid pro®le determination. Results: All patients included completed the study. Comparisons were made between means of lipid pro®le constituents after the placebo and active product periods. These showed signi®cant mean reduction of 5.3% (P 0.004) for total cholesterol, 6.15% (P 0.012) for LDL-cholesterol and no signi®cant variation for HDLcholesterol and triglycerides. The majority of patients presented no variation or had a decrease in their total cholesterol level. However, during the active product period, three patients showed an increase in cholesterol level by more than 5%. Conclusion: The fermented milk (Gaio 1 ) produced a small but statistically signi®cant decrease in total and LDL-cholesterol mean. However, not all subjects seem to respond to the product, and a few subjects showed a cholesterol increment. Further investigations are necessary to clarify this aspect.
Introduction
Similarly to the situation throughout the western world, coronary artery disease is one of the most frequent causes of morbidity and mortality in Brazil (Lotufo, 1996) . It is known that individuals presenting some conditions, designated as risk factors, have a higher chance of prematurely developing this disease. Among the risk factors, hypercholesterolemia is one of the most important (NCEP Adult Treatment Panel, 1993) . However, cases of very high cholesterol levels are not frequent, so they are not responsible for a large number of cases of symptomatic coronary disease. The vast majority of these cases consists of individuals presenting cholesterol considered to be in thè normal' (mean) range or slightly increased (Martin et al, 1986; Kannel, 1995) . These people in general also have other risk factors, including smoking, hypertension, diabetes mellitus, sedentary lifestyle, excess weight, stress, and so on, mainly because modern life predisposes to them. It was demonstrated by Downs et al (1998) that healthy people presenting cholesterol level within the`normal' range have a reduction in the risk of future cardiovascular events when their cholesterol level is decreased. Consequently, any procedure that could help to decrease serum cholesterol in people in whom it is not too elevated and who have been unable to obtain signi®cant improvement following a cholesterol lowering diet, would be very welcome.
The question whether lactic acid bacteria can be bene®cial to health was posed long ago, and so far no clear answer is available. It is even more dif®cult to determine a speci®c possible mechanism if any real improvement of health is observed. One possibility is that milk and fermented milk products have an effect on serum lipids and lipoproteins, inducing a better lipid pro®le. Not all studies reach the same conclusion, as discussed by Eichholzer & Sta Èhelin in an extensive review of this subject (Eichholzer & Sta Èhelin, 1993) and more recently by the Mission Scienti®que de Syndifrais (1997) .
A group at Kiev University (KG Sarkisov, EP Podrushmyak and YG Grigorov, unpublished observations) demonstrated a signi®cant hypocholesterolemic effect utilizing a milk product fermented with bacteria isolated from Abkhasia in the Caucasus. This region is reputed for the longevity of its people and it is known that fermented milk is a major part of the traditional diet of this population, suggesting a link between these two ®ndings. Agerbaek et al (1995) and Richelsen et al (1996) have shown that a new yogurt-like product (Gaio 1 weeks and for 6 months was able to signi®cantly reduce LDL-cholesterol level by about 10%. However, these authors studied only volunteers presenting a median cholesterol level and consuming their regular diets. The product was similar to that used in the study of the Kiev University but was produced in Denmark.
We planned a study to test the use of Gaio 1 in a mild to moderate hypercholesterolemic population previously subjected to a restricted diet intended to reduce their cholesterol level.
The objective of this study was to evaluate the effects over the lipid pro®le of a new product of fermented milk (Gaio 1 ) with cultures of bacteria obtained from the intestinal¯ora of the Abkhasian people (Caucasians) in patients with mild to moderate primary hypercholesterolemia.
Materials and methods
The milk product Vigor Company supplied the fermented milk product (Gaio 1 ), in accordance with MD Foods (from Denmark). The original Ukrainian bacterial culture (Causido 1 ) was used. This culture contains one human species of Enterococcus faecium and two strains of Streptococcus thermophilus. The colony-forming units of the fresh product were 10 5 ± 10 9 aml for E. faecium and 5 ± 20610 8 aml for S. thermophilus (Agerbaek et al, 1995) . Per hundred grams, the product (and the placebo) has an energy content of 240 kJ and contains 4.9 g protein, 5.4 g carbohydrate and 1.5 g fat (2a3 as milk fat and 1a3 as soybean fat). The cholesterol content was about 5 mg per 100 g of the product. Vitamins E and C were added in accordance with the original Ukrainian recipe, giving ®nal concentrations of 0.5 mg and 10 mg, respectively, per 100 g. The placebo product was of identical composition but was chemically fermented with organic acid (glucone aciddelta-lactone) and without the bacterial culture. Distribution of the two products was made directly by Vigor to the residence of each participant on a weekly basis, after veri®cation of the regular consumption of the amount delivered at the previous visit. The bacteria in the Causido 1 product were counted for each new production series, con®rming that the numbers were constant during the study period.
Subjects
According to a protocol previously de®ned we studied 32 patients (21 women, 11 men) with primary hypercholesterolemia routinely followed by the Dislipidemia Medical Section of the Instituto Dante Pazzanese de Cardiologia de Sa Äo Paulo. Patients' ages ranged between 36 and 65 years (mean 55.69, s.d.7.72 ). All of them were on a controlled diet as previously implemented for at least 8 weeks (see below) and this was reinforced at each visit for clinical and laboratory evaluation. All patients had LDLcholesterol level higher than 130 mgadl and below 220 mgadl and triglycerides below 350 mgadl after the 8-week diet period. All patients had primary hypercholesterolemia. Patients with diabetes, hypothyroidism, nephrotic syndrome, obesity (body mass index!30), or regular consumption of alcoholic beverages (de®ned as the intake of more than three doses of any kind of alcoholic beverage per week) were not included. No patient was using a lipidlowering drug, neither antifungical or immunosuppressant regimens. All patients using antihypertensive medication maintained the same regimen during the period of the study. Since the use of any antibiotic treatment during the study period could have interfered with the results, patients were warned to notify the staff if they had to take medication of this kind. The protocol was reviewed and authorized by the Ethical Committee of Instituto Dante Pazzanese de Cardiologia. Patients received orientation about the study and signed an informed consent previously to their inclusion in the study.
The prescribed diet followed during the study period was that of Phase I of the American Heart Association (NCEP Adult Treatment Panel, 1993) . This diet is composed of approximately 30% of the total daily caloric intake as fat (maximum of 10% for saturated, 10% for polyunsaturated and 10% for monounsaturated) and a maximum of 300 mg daily of cholesterol. Remaining calories were distributed between carbohydrates (about 50%) and proteins (about 20%).
Characteristics of the patients involved in the study are described in Table 1 .
Experimental design
The study was prospective, randomized, double-blinded and placebo controlled, with a crossover design. Vigor personnel made the randomization by draw. After initial clinical and laboratory analysis, patients began to take 200 g daily of Gaio 1 or its placebo in a randomized and double-blind manner. Seventeen patients started the trial using the active product and 15 began with placebo. After 8 weeks, blood was collected again for lipid pro®le evaluation and the crossover was made (those consuming Gaio 1 changed to placebo and vice versa). After an additional 8 weeks, blood was collected for another lipid pro®le determination. Patients were instructed to consume the milk product (test product or placebo) once daily with the ®rst meal of the day (breakfast) and not to take any other forms of fermented milk products than those delivered for the study. The study began in June 1996, with patients' inclusion lasting until August. The study ended in the middle of December 1996.
Experimental procedures
Patients returned for evaluation during the morning after 12 ± 24 h fasting. They were submitted to a medical interview including history and record of any complaints, diet and product adherence questionnaires, physical examination and weight determination, and blood samples were taken for lipid analyses. Cholesterol and triglyceride determinations were made by enzymatic methods and LDLcholesterol was determined by the Friedewald formula (Friedewald et al, 1972) . For statistical analysis the 32 patients were considered in three phases: phase 1, only in regular use of oriented dietary control (maintained also for the other phases); phase 2, after 8 weeks consuming placebo; phase 3, after 8 weeks consuming Gaio 1 . The bimodal paired t-test was used for the evaluation of observed mean differences of each lipid pro®le variable and patients' weight for each phase. A P value`0.05 was considered signi®cant.
Results
All patients included completed the study.
Mean and standard deviation for each variable of the lipid pro®le and weight in each phase of the study are shown in Table 2 , which also shows when signi®cant differences were found between phases. Table 3 shows percentage variation of total cholesterol and LDL-cholesterol during the study phases.
The fact that total cholesterol was measured directly whereas LDL-cholesterol was calculated including the measurements of HDL-cholesterol and triglycerides could increase determination error. To avoid this, we considered primarily total cholesterol as the main objective of this study.
Total cholesterol
The comparison between means observed after phase 1 when patients were only under diet and phase 2 when they were also taking placebo showed no signi®cant difference. The comparison between means observed after phase 1 (diet only) and phase 3 when patients were taking the active product showed signi®cant mean reduction of 12.72 mgadl (95% CI 2.98 ± 22.45) (P 0.012). The comparison between means observed after phase 2 (placebo) and phase 3 (active product) showed signi®cant mean reduction of 13.34 mgadl (95% CI 4.95 ± 22.10) (P 0.004). Mean reduction was 5.3% (9.4%) with maximum decrease of 23.4% and maximum increase of 18.8%.
Phase 2 (placebo) and phase 3 (active product) represented more similar conditions because in both periods patients took daily a product and neither they nor the researchers knew whether it was active or not (double blind). We analyzed cases individually, comparing total cholesterol determined after these two phases, considering up to 5% as an acceptable analysis variation due to the laboratory method. We could distinguish that 13 cases did not vary (had a total cholesterol variation between the two phases less than 5%), 16 cases had a reduction of their cholesterol level (more than 5%) and 3 cases had an increase in cholesterolemia (more than 5%). The three cases that showed increase in total cholesterol had variation of 14.44% (case 3), 18.77% (case 7) and 5.76% (case 12).
Triglycerides
The comparisons between mean triglyceridemia observed after the three phases did not show signi®cant differences.
HDL-cholesterol
The comparison between means observed after phase 1 (diet only) and phase 2 (placebo) showed signi®cant elevation (P 0.001). The comparisons between means observed after phase 1 (diet only) 3 (active product) and after phases 2 (placebo) and 3 (active product) did not show signi®cant differences. Comparison between means observed after phases 1 (diet only) and 3 (active product); P 0.002. e Comparison between means observed after phases 2 (placebo) and 3 (active product); P 0.012. f Comparison between means observed after phases 1 (diet only) and 2 (placebo); P 0.026. g Comparison between means observed after phases 1 (diet only) and 3 (active product); P 0.014. Fermented milks and primary hypercholesterolemia MC Bertolami et al
LDL-cholesterol
The comparison between means observed after phase 1 (diet only) and phase 2 (placebo) did not show signi®cant difference. The comparison between means observed after phase 1 (diet only) and phase 3 (active product) showed signi®cant mean reduction of 14.22 mgadl (95% CI 5.66 ± 22.78) (P 0.002). The comparison between means observed after phase 2 (placebo) and phase 3 (active product) showed signi®cant mean reduction of 10.59 mgadl (95% CI 2.48 ± 18.74) (P 0.012). Reduction mean was 6.15% (12.7%).
Weight
The comparison between means observed after phase 1 (diet only) and phase 2 (placebo) showed signi®cant reduction (P 0.026). The comparison between means observed after phase 1 (diet only) and phase 3 (active product) showed signi®cant reduction (P 0.014). Finally, the comparison between means observed after phase 2 (placebo) and phase 3 (active product) did not show signi®cant difference.
Other variables
There were no signi®cant changes in blood pressure, serum glucose, creatinine, urea and uric acid, which were always measured when patients returned for each visit. None of the patients reported any alteration in diet, alcohol intake, tobacco consumption or physical activity during the period of the study.
Side-effects and adherence
Both products were well tolerated and compliance was good. One patient stopped placebo use for one week because she underwent cataract surgery and needed to use antibiotics. Another patient stopped the use of Gaio 1 some days after the start because she had to travel for ®ve days and resumed after that interval. Two patients complained of nausea while they were using the placebo product, but ®nished all the study period.
Discussion
The new fermented milk based on the Abkhasia product was shown to have the capacity of decreasing cholesterol level in three previous studies (KG Sarkisov, EP Padrushmyak and YG Grigorov, unpublished observations; Agerbaek et al, 1995; Richelsen et al, 1996) that analyzed people with`normal' blood cholesterol level and following their regular diets. The present study involved a population with mild to moderate hypercholesterolemia that did not show a signi®cant improvement with dietetic modi®cations alone. It showed that the Gaio 1 product was able to signi®cantly reduce total cholesterol and LDL-cholesterol means in this population.
As far as we know, the present study is the ®rst in the literature to involve people presenting mild to moderate hypercholesterolemia. Patients were subjected initially to a period of only dietary advice intended to reduce their cholesterol levels, which was not entirely ef®cacious. After that period the same patients underwent a period taking yogurt and another period taking its placebo, or vice versa. The comparison between these two periods showed a reduction in means of total cholesterol and LDL-cholesterol but some patients experienced an elevation of their cholesterol levels both during the use of placebo and in the active period.
We do not know how to explain the observed increase in total cholesterol presented by three patients under the action of Gaio 1 . None of these patients had weight elevation, disregarded dietary advice, or other cause that could explain the observed increase. All of these patients were women, probably coincidentally since there was a higher number of women than men enrolled in the study. Although one study showed that yogurt was hypocholesterolemic for female but not for male human subjects (Bazzare et al, 1983) , it is very unlikely, according to the study of Richelsen et al (1996) , that there is a gender difference response to Gaio 1 . Considering phases 1 and 2 (diet only and diet plus placebo), there were also some patients who had an increase higher than 5%, namely patients 1 (7.44%), 2 (9.73%), 3 (7.57%), 5 (8.4%), 8 (13.45%), 9 (6.9%), 25 (9.43%), 30 (7.29%) and 31 (11.63%). Of these patients 3 were men and 6 were women.
All female patients but one enrolled in this study were postmenopausal. The one premenopausal women used oral contraceptives throughout the study period. She presented a total cholesterol reduction of 17.01% using the active product compared to the placebo period. Two women were using estrogen replacement throughout the study period. One presented no signi®cant variation (72.01%) and the other presented a decrease (714.87%) in the total cholesterol level under the use of Gaio 1 compared to the placebo phase.
The possibility that these patients who presented an increase in total cholesterol have especially high sensitivity to the fat contained in the product seems unlikely because although the cholesterol elevation occurred both during placebo use and during Gaio 1 use, different patients presented increases when using placebo and the active product. If this is not the case and the only difference between Gaio 1 and the placebo product is the presence of the bacterial culture (Causido culture), this should be able to increase the cholesterol level. From the available literature, this latter suggestion seems very unlikely. Some patients had increases in their cholesterol level during the use of placebo but the majority of them had a reduction after the use of Gaio 1 . The inverse situation, i.e. a decrease during the use of placebo and an increase during the active product was not seen in any case. Another possibility is that a laboratory variation higher than usual was responsible for the increase in cholesterol level, but this also is very unlikely because during the use of Gaio 1 we made an intermediate blood collection that con®rmed the elevation observed at the end of the active treatment period. Perhaps a biological variation greater than usual for normocholesterolemic people can apply to mild to moderate hypercholesterolemic patients. This problem of increased cholesterol level during the use of Gaio 1 presented by some patients negates the potential recommendation of this product to a person presenting hypercholesterolemia in the clinical practice.
No correlation was found between the percentage of variation of total cholesterol (comparing phase 3 (after Gaio 1 ) and phase 2 (after placebo)) and variables measured after the placebo phase such as weight, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol and age. Richelsen et al (1996) found a tendency to higher initial HDL-cholesterol and higher alcohol consumption among those whom they considered as non-responders (people who had no variation in LDL-cholesterol and even an increment after 3 months of Gaio 1 use). We did not observe any of these effects in our study which took place during a shorter period of time. A fundamental question raised by this study is whether the statistically signi®cant reduction of total and LDLcholesterol under the use of Gaio 1 of approximately 5% is clinically important. There are no data showing that small reductions similar to the ones achieved here are bene®cial for the prevention of atherosclerotic manifestations, the ultimate goal of cholesterol-lowering therapy. An important issue that is still unanswered is whether the cholesterol reduction presented by the consumption of Gaio 1 is sustained long-term. This question was addressed by Riechelsen et al (1996) . These authors showed that after 1 month of Gaio 1 use there was a signi®cant decrease in LDL-cholesterol level. After 6 months, although the effect remained, it showed no statistical difference compared to the reduction presented by the control group. As other studies have shown that to improve risk status cholesterol lowering has to be maintained for at least 6 months (Sacks et al, 1996) to 1 year (Scandinavian Simvastatin Survival Study Group, 1995; Shepherd et al, 1995) , it is still uncertain whether fermented milk can produce bene®ts to lipid status for so long a time. A recent investigation showed that cholesterol lowering induced by Simvastatin can improve endothelial function within 1 month (O'Driscoll et al, 1997) but the clinical importance of this ®nding remains unknown. More research is needed with more subjects and for longer times to clarify these aspects.
Conclusion
The fermented milk (Gaio 1 ) produced small but statistically signi®cant mean decreases in total and LDL-cholesterol of 75.3% and 76.15%, respectively. Accordingly, this fermented milk seems to have had some generally bene®cial effects on the cholesterol level in the hypercholesterolemic subjects in the present study. However, several points still require clari®cation. (1) Not all subjects seem to respond to the product. (2) There is suspicion that a few subjects may even have suffered adverse effects (increment of cholesterol) with the product. (3) What is the effect during long-term treatment? Accordingly, further investigations are necessary to clarify these questions before ®rm conclusions can be reached concerning the effect of this fermented milk on the cholesterol level.
